Background Pneumococcal community-acquired pneumonia (pCAP) is the most frequent
form of pneumonia. The elderly and adults with underlying diseases are at an increased risk …

Adult vaccination is high on the agenda in many countries. Two different vaccines are
available for the prevention of pneumococcal disease in adults: a 23-valent polysaccharide …

Background Data on the efficacy of the 23-valent pneumococcal polysaccharide vaccine
(PPV-23) in preventing adult community-acquired pneumonia (CAP) among the target …

Two pneumococcal vaccines currently exist and have been recommended for the prevention
of pneumococcal infection in adults 65 years of age and older: the 23-valent polysaccharide …

Background Routine vaccination of elderly people against pneumococcal diseases is
recommended in many countries. National guidelines differ, recommending either the 23 …

Introduction. Incidence of invasive pneumococcal diseases (IPDs) in Italy is constantly
increasing and that is particularly true among the elderly. 23-valent polysaccharide …

The efficacy of PPV-23 vaccine on outcomes of pneumococcal disease in adults still remains
controversial due mainly to the lack of consistency between the results obtained from …

Background. The benefits of using the 23-valent pneumococcal polysaccharide vaccine
(PPV23) are controversial. This study assessed clinical effectiveness of PPV23 in preventing …

Introduction S. pneumoniae can cause a wide spectrum of diseases, including invasive
pneumococcal disease and pneumonia. Two types of pneumococcal vaccines are indicated …

Background Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23)
is available in the United Kingdom to adults aged 65 years or older and those in defined …